BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-508@pharmaconomics
DTSTAMP:20260707T032618Z
DTSTART;VALUE=DATE:20260615
DTEND;VALUE=DATE:20260616
SUMMARY:GOSS AdCom — seralutinib
DESCRIPTION:An FDA advisory committee reviews seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) around Jun 15\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518xexx991xearni.htm\n\nTrack it: https://pharmaconomics.com/e/508
URL:https://pharmaconomics.com/e/508
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GOSS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR